| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9867815 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10016407 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10413505 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10933060 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10987347 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10973811 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US11040032 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10420760 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10894012 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10149843 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10231961 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
| US10857095 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
Goprelto is owned by Genus Lifesciences.
Goprelto contains Cocaine Hydrochloride.
Goprelto has a total of 12 drug patents out of which 0 drug patents have expired.
Goprelto was authorised for market use on 14 December, 2017.
Goprelto is available in solution;nasal dosage forms.
Goprelto can be used as method of administering a local anesthetic to the mucous membranes in patients with renal impairment, method of administering a local anesthetic to the mucous membranes in geriatric patients, method of administering a local anesthetic to the mucous membranes, method for the induction of local anesthesia prior to performing a procedure on, through, or adjacent to the mucous membranes, method of administering a local anesthetic prior to performing a diagnostic or surgical procedure on a subject with hepatic or renal impairment, method of administering a local anesthetic to the mucous membranes in patients with hepatic impairment, method for the induction of local anesthesia of the mucous membranes.
Drug patent challenges can be filed against Goprelto from 14 December, 2021.
The generics of Goprelto are possible to be released after 07 February, 2037.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 14, 2022 |
Drugs and Companies using COCAINE HYDROCHLORIDE ingredient
NCE-1 date: 14 December, 2021
Market Authorisation Date: 14 December, 2017
Treatment: Method of administering a local anesthetic to the mucous membranes in geriatric patients; Method of administering a local anesthetic prior to performing a diagnostic or surgical procedure on a subject...
Dosage: SOLUTION;NASAL
GOPRELTO family patents
